Skip to main content

Table 1 Clinical and biological data from the 48 patients included in the microarray analysis

From: Two independent epigenetic biomarkers predict survival in neuroblastoma

  INRG staging system
Characteristics L1 L2 M MS Total
Number of patients 10 16 18 4 48
Pre-treatment risk group
  Very low + low 10 2 0 3 15
  Intermediate 0 10 2 0 12
  High 0 4 16 1 21
Age at diagnostic in months
  Median 11.1 18.6 27.6 4 16.1
  Range 1.5-22.7 4.8-109.3 6.6-79.8 1.9-6.7 1.5-109.3
Patients over 18 months at diagnostic 4 9 11 0 24
Sex
  Female 6 8 6 2 22
  Male 4 8 12 2 26
Primary site
  Adrenal 1 5 9 3 18
  Abdominal 4 5 2 0 11
  Cervical 0 1 0 1 2
  Thoracic 2 0 4 0 6
  Cervical-thoracic 0 1 0 0 1
  Thoracic-abdominal 1 1 0 0 2
  Pelvic 1 0 0 0 1
  Other sites 1 3 3 0 7
Protocol of treatment
  LNESG I 2 0 0 0 2
  LNESG II 1 0 0 0 1
  EUNS 0 2 0 0 2
  INES 3 5 2 2 12
  HR-NBL-1 0 4 9 0 13
  Other (national protocols) 4 4 7 2 17
MYCN status
  Amplified (%) 0 (0%) 4 (25%) 8 (44%) 1 (25%) 13 (27%)
  Not amplified (%) 10 (100%) 12 (75%) 10 (56%) 3 (75%) 35 (73)
1p status
  Normal (%) 8 (80%) 8 (50%) 8 (44%) 3 (75%) 27 (56%)
  Deleted (%) 0 (0%) 4 (25%) 7 (39%) 0 (0%) 11 (23%)
  Not determined (%) 2 (20%) 4 (25%) 3 (17%) 1 (25%) 10 (21%)
Patients with relapse (%) 1 (10%) 7 (44%) 11 (61%) 1 (25%) 20 (42%)
Type of relapse
  Local 1 5 2 0 8
  Metastatic 0 1 3 1 5
  Local + metastatic 0 1 6 0 7
Dead (%) 0 (0%) 5 (32%) 12 (67%) 1 (25%) 18 (38%)
Cause of death
  Disease progression 0 4 11 1 16
  Other 0 1 1 0 2
Time of follow-up (month)
  Median 152.1 93.5 45.4 129.3 117.4
  Range 87.8-208.3 9.4-206.5 3.4-161.2 17.2-214.9 3.4-214.9